Related Experiment Video
Updated: Sep 27, 2025
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer
Madhu Sharma1, Avijit Kumar Bakshi2, Naresh Mittapelly2
1Division of Pharmaceutics & Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, UP, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
Abstract:
The multi-dimensional challenge of drug resistance is one of the pivotal hindrances for cancer chemotherapy. A reductive approach to define and distinguish the main aspects of drug resistance, such as tumor growth kinetics about tumor micro-environment (tumor multifariousness), therapeutic pressure, physical barricades, irreversible genetic mutation, as well as role of the immune system, are the main causes of failure in cancer therapy are presented systematically. We are focusing on general approaches to reduce drug resistance: earlier diagnosis of tumors allowing for cancer halting; dynamic surveillance throughout treatment; the adding of new therapeutic strategies and improve pharmacodynamics precepts resulting in profound effects; and identification of cancerous cells repositories using high-throughput monitoring, as well as the interoperability of clinical- gene mapping statics are described in detail. These strategies could be potentially constructed for any tumor at any precise moment and used to guide therapy selection. Chemotherapeutic agents results in mild improved survival in clinical trials owing to several pathophysiologic obstacles, such as intra-tumoral dispersion, invasion & intra-cellular transportation. This review highlights recent advancements in developing new therapeutic innovations to combat drug resistance in cancer therapy by overcoming various barricades in the tumor microenvironment.
Insights
Drug resistance in cancer chemotherapy is a major challenge. This review outlines strategies like early diagnosis, dynamic monitoring, and novel therapies to overcome resistance and improve patient outcomes.
Area of Science:
- Oncology
- Cancer Therapeutics
- Drug Resistance
Background:
- Drug resistance is a primary cause of chemotherapy failure.
- Factors contributing to resistance include tumor microenvironment, genetic mutations, and immune system evasion.
- Current chemotherapeutic agents show limited efficacy due to pathophysiological obstacles.
Purpose of the Study:
- To systematically define and distinguish the main aspects of cancer drug resistance.
- To present general approaches for reducing drug resistance in cancer therapy.
- To highlight recent advancements in therapeutic innovations against cancer drug resistance.
Main Methods:
- Systematic review of factors contributing to drug resistance.
- Analysis of general strategies to reduce drug resistance, including early diagnosis and dynamic surveillance.
- Exploration of novel therapeutic strategies and high-throughput monitoring for identifying cancer cell repositories.
Main Results:
- Identified key factors of drug resistance: tumor multifariousness, therapeutic pressure, genetic mutations, and immune system role.
- Described strategies for reducing drug resistance: early diagnosis, dynamic surveillance, new therapeutic approaches, and improved pharmacodynamics.
- Highlighted the potential of high-throughput monitoring and clinical-gene mapping for guiding therapy selection.
Conclusions:
- Overcoming drug resistance requires a multi-dimensional approach.
- Early diagnosis, dynamic treatment monitoring, and innovative therapies are crucial for improving cancer treatment outcomes.
- Advanced monitoring techniques and personalized medicine strategies hold promise for combating cancer drug resistance.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
09:58Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
Related Concept Videos
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...